Total Payments
$33,179
2024 Payments
$1,660
Companies
15
Transactions
64
Medicare Patients
618
Medicare Billing
$41,089
Payment Breakdown by Category
Research$25,704 (77.5%)
Travel$5,466 (16.5%)
Food & Beverage$1,020 (3.1%)
Consulting$990.00 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $25,704 | 9 | 77.5% |
| Travel and Lodging | $5,466 | 10 | 16.5% |
| Food and Beverage | $1,020 | 44 | 3.1% |
| Consulting Fee | $990.00 | 1 | 3.0% |
Payments by Type
Research
$25,704
9 transactions
General
$7,476
55 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $25,704 | 9 | $0 (2024) |
| Avid Radiopharmaceuticals, Inc. | $3,000 | 1 | $0 (2022) |
| Merck Sharp & Dohme LLC | $1,686 | 10 | $0 (2023) |
| ModernaTX, Inc. | $1,338 | 9 | $0 (2024) |
| Genentech, Inc. | $990.00 | 1 | $0 (2022) |
| Novo Nordisk Inc | $99.74 | 7 | $0 (2020) |
| PFIZER INC. | $83.70 | 6 | $0 (2021) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $72.85 | 6 | $0 (2021) |
| Amgen Inc. | $61.38 | 4 | $0 (2019) |
| Allergan Inc. | $31.84 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,660 | 11 | ModernaTX, Inc. ($1,338) |
| 2023 | $3,677 | 12 | Eli Lilly and Company ($2,002) |
| 2022 | $23,366 | 5 | Eli Lilly and Company ($19,376) |
| 2021 | $4,035 | 3 | Eli Lilly and Company ($4,005) |
| 2020 | $16.76 | 1 | Novo Nordisk Inc ($16.76) |
| 2019 | $39.13 | 3 | GlaxoSmithKline, LLC. ($13.67) |
| 2018 | $188.23 | 14 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($58.68) |
| 2017 | $197.10 | 15 | Novo Nordisk Inc ($54.63) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/23/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $317.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $448.94 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $265.53 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | In-kind items and services | $240.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $120.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $81.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Travel and Lodging | Cash or cash equivalent | $77.81 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $45.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 09/14/2024 | ModernaTX, Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 04/09/2024 | Eli Lilly and Company | — | — | In-kind items and services | $4.26 | Research |
| Study: A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $526.69 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $501.34 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $56.32 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $46.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $46.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $32.63 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/14/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $254.90 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/14/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $116.52 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/14/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $94.06 | General |
| Category: CARDIOVASCULAR | ||||||
| 04/28/2023 | Eli Lilly and Company | — | — | In-kind items and services | $195.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
| 01/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $1,586.75 | Research |
| Study: A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | ||||||
| 01/09/2023 | Eli Lilly and Company | — | — | In-kind items and services | $220.00 | Research |
| Study: A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | ||||||
| 10/04/2022 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $990.00 | General |
| 05/20/2022 | Eli Lilly and Company | — | — | In-kind items and services | $2,654.00 | Research |
| Study: A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $19,895 | 2 |
| A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $2,654 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $1,587 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $832.00 | 1 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $512.00 | 2 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $220.00 | 1 |
| A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | Eli Lilly and Company | $4.26 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 3 | 84 | 92 | $14,583 | $5,973 |
| 2020 | 7 | 534 | 603 | $63,676 | $35,116 |
Total Patients
618
Total Services
695
Medicare Billing
$41,089
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 27 | 27 | $5,253 | $3,502 | 66.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 45 | 53 | $7,062 | $1,776 | 25.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 12 | 12 | $2,268 | $694.43 | 30.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 136 | 136 | $23,120 | $15,341 | 66.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 107 | 149 | $16,390 | $6,742 | 41.1% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2020 | 95 | 95 | $7,220 | $5,795 | 80.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 31 | 47 | $7,520 | $3,498 | 46.5% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 56 | 67 | $4,422 | $1,602 | 36.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 97 | 97 | $3,492 | $1,578 | 45.2% |
| 99497 | Advance care planning by the physician or other qualified health care professional | Office | 2020 | 12 | 12 | $1,512 | $560.74 | 37.1% |
About Dr. Robert Cupelo, M.D
Dr. Robert Cupelo, M.D is a Internal Medicine healthcare provider based in East Syracuse, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1750371548.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Cupelo, M.D has received a total of $33,179 in payments from pharmaceutical and medical device companies, with $1,660 received in 2024. These payments were reported across 64 transactions from 15 companies. The most common payment nature is "" ($25,704).
As a Medicare-enrolled provider, Cupelo has provided services to 618 Medicare beneficiaries, totaling 695 services with total Medicare billing of $41,089. Data is available for 2 years (2020–2021), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location East Syracuse, NY
- Active Since 10/24/2005
- Last Updated 05/11/2011
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1750371548
Products in Payments
- XIFAXAN (Drug) $72.85
- ELIQUIS (Drug) $72.27
- Aimovig (Biological) $31.98
- Ozempic (Drug) $31.04
- SYMBICORT (Drug) $25.86
- VIBERZI (Drug) $17.76
- BREO (Drug) $16.59
- Repatha (Biological) $16.20
- NAMZARIC (Drug) $14.08
- Tresiba (Drug) $14.07
- ANORO (Drug) $13.67
- EVENITY (Biological) $13.20
- SPIRIVA (Drug) $12.40
- VIAGRA (Drug) $11.43
- JARDIANCE (Drug) $11.13
- Vascepa (Drug) $10.76
- PRALUENT (Drug) $10.60
- TOUJEO (Drug) $10.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in East Syracuse
Ajeet Gajra, Md, MD
Internal Medicine — Payments: $87,892
Internal Medicine $87,892
Brian Raphael, M.d, M.D
Internal Medicine — Payments: $10,696
Internal Medicine $10,696
Dr. Steven Duffy, Md, MD
Internal Medicine — Payments: $7,620
Internal Medicine $7,620
Dr. Suhayb Kadura, M.d, M.D
Internal Medicine — Payments: $3,921
Internal Medicine $3,921
Michael Brodowski, M.d, M.D
Internal Medicine — Payments: $2,994
Internal Medicine $2,994
Dr. Diana Christensen, Md, MD
Internal Medicine — Payments: $1,814
Internal Medicine $1,814